The role of ApoB rs1042034 gene polymorphism on clinical outcomes of ischemic stroke patients in Yogyakarta

Abstract Background Increasing lipid level in blood as one of the predictor factors causing stroke, has several genes that influence it, one of which is Apolipoprotein B (ApoB). The genetic polymorphisms ApoB rs1042034 (G/A) and ApoB rs676210 (G/A) which correlate with increased triglyceride and decrease HDL levels, are thought to influence the clinical outcomes of acute ischemic stroke patients. This research examines the differences lipid profiles and clinical outcomes of each genotype for the ApoB rs1042034 (G/A) and ApoB rs676210 (G/A) polymorphisms in acute ischemic stroke patients in Yogyakarta. The samples used were whole blood samples from 110 acute ischemic stroke patients. Subjects were divided into two groups, namely subjects with moderate clinical outcome scores (NIHSS 5–14) and mild clinical outcome scores (NIHSS < 5). All blood samples will be checked for their genotype using PCR RFLP, ands will be confirmed using Sanger sequencing. Results The frequency distribution of the ApoB rs1042034 (G/A) genotype in both case and control groups was obtained in the additive model; the AA genotype gave significant results of the good clinical outcome (OR:0, 231; CI: 0, 161–0, 867; p:0, 046), in the recessive model, the GA + GG genotype was more at risk of experiencing poor clinical outcomes than the AA genotype (OR:4, 533; CI:1, 267–16, 220; p:0, 022). Multivariate analysis showed that the variables that had the most influence on clinical outcomes were AA genotype (OR:0, 230; OR:0, 059–0, 901; p:0, 035). Conclusions The ApoB rs1042034 polymorphism, particularly the AA genotype, proved a notable protective effect in modifying adverse clinical outcomes.